Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 28, Number 1—January 2022
Dispatch

SARS-CoV-2 RNA Shedding in Semen and Oligozoospermia of Patient with Severe Coronavirus Disease 11 Weeks after Infection

Lawrence J. PurpuraComments to Author , Joseph Alukal, Alexander M. Chong, Lihong Liu, Anyelina Cantos, Jayesh Shah, Nicola Medrano, Jennifer Y. Chang, Moriya Tsuji, Hiroshi Mohri, Anne Catrin Uhlemann, David Ho, and Michael T. Yin
Author affiliations: Columbia Mailman School of Public Health, New York, New York, USA (L.J. Purpura); Columbia University Irving Medical Center, New York (L.J. Purpura, J. Alukal, A.M. Chong, L. Liu, A. Cantos, J. Shah, N. Medrano, J.Y. Chang, M. Tsuji, H. Mohri, A.C. Uhlemann, D. Ho, M.T. Yin)

Main Article

Figure 1

IgA, IgM, and IgG antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, receptor-binding domain (RBD), and nucleocapsid protein (NP) for participant 1 at days 72 and 78 from symptom onset. A) C0087 plasma SARS-CoV-2 spike-specific IgA; B) C0087 plasma SARS-CoV-2 spike-specific IgM; C) C0087 plasma SARS-CoV-2 spike-specific IgG; D) C0087 plasma SARS-CoV-2 spike/RBD‒specific IgA; E) C0087 plasma SARS-CoV-2 spike/RBD‒specific IgM; F) C0087 plasma SARS-CoV-2 spike/RBD‒specific IgG; G) C0087 plasma SARS-CoV-2 NP-specific IgA; H) C0087 plasma SARS-CoV-2 NP-specific IgM; I) C0087 plasma SARS-CoV-2 NP-specific IgG. OD450, optical density at 450 nm.

Figure 1. IgA, IgM, and IgG antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, receptor-binding domain (RBD), and nucleocapsid protein (NP) for participant 1 at days 72 and 78 from symptom onset. A) C0087 plasma SARS-CoV-2 spike-specific IgA; B) C0087 plasma SARS-CoV-2 spike-specific IgM; C) C0087 plasma SARS-CoV-2 spike-specific IgG; D) C0087 plasma SARS-CoV-2 spike/RBD‒specific IgA; E) C0087 plasma SARS-CoV-2 spike/RBD‒specific IgM; F) C0087 plasma SARS-CoV-2 spike/RBD‒specific IgG; G) C0087 plasma SARS-CoV-2 NP-specific IgA; H) C0087 plasma SARS-CoV-2 NP-specific IgM; I) C0087 plasma SARS-CoV-2 NP-specific IgG. OD450, optical density at 450 nm.

Main Article

Page created: October 01, 2021
Page updated: October 13, 2021
Page reviewed: October 13, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external